AlphAIAlphAI — Financial news for AI agents
tradingview.com

StoneX maintains Intensity Therapeutics at Speculative Buy, lowers price target to $8 from $12

StoneX kept Intensity Therapeutics at Speculative Buy but cut its price target to $8 from $12, a 33.3% reduction. The new target suggests a 158.1% upside from the Nov 5 close of $3.10.

Original reporting
tradingview.com
Published Nov 6, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
StoneX maintains Intensity Therapeutics at Speculative Buy, lowers price target to $8 from $12 — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's target reduction signals a bearish outlook, likely prompting short‑term selling.

02

Market read

Analyst downgrade on a micro‑cap biotech may trigger price decline and affect sector sentiment.

03

What to watch

Potential pipeline milestones not reflected in the target change.

Relevance 5/10Novelty 5/10Timing: today

Background

Intensity Therapeutics is a clinical‑stage biotech focused on metabolic diseases.

Market effects

Sector

May weigh on other small‑cap biotech stocks as analysts reassess valuation multiples.

Regional

Limited to US biotech sector.

Global

Minimal.

Counterpoint

What could challenge this read

Target cut could be overly pessimistic if upcoming trial data exceeds expectations.

Key entities

  • Analyst
    StoneX

    Research firm that issued the price target downgrade.

  • Company
    Intensity Therapeutics

    Biotech firm receiving the downgraded target.

Read at source← All news

Related articles

$BLSHHighAI 8/10

Bullish stock initiated at Buy by StoneX on tokenization potential

StoneX initiated coverage on Bullish (NYSE:BLSH) with a Buy rating and $42 price target, citing tokenization potential. The company's shares have fallen 48% since September, trading at $21.31. Bullish plans to acquire Equiniti, positioning it as a transfer agent for public companies. Analysts have mixed views on the acquisition, with some upgrading and others lowering targets.

investing.com
$RXOMedAI 8/10

RXO stock holds at StoneX as freight rates improve ahead of CHRW deal

StoneX reiterated a Hold rating on RXO, Inc. (NYSE:RXO) after its Q3 adjusted EBITDA of $51M exceeded estimates. RXO's truckload gross profit and margins improved, with spot rates and contract pricing supporting brokerage margins. RXO's stock has surged 120% YTD. C.H. Robinson's $5.8B acquisition of RXO is pending, with mixed analyst reactions on ratings and price targets.

investing.com
$GMEHigh

StoneX Makes Major Call on GameStop Stock

StoneX initiated coverage of GameStop (GME) with a Buy rating and $33 price target, citing confidence in its transformation. Analyst Mike Hickey highlighted Ryan Cohen's rebuilding efforts and the growth in collectibles. Q2 revenue fell 18.7% but operating income rose to $160.2M, with collectibles revenue up 56.5%. The company is shifting focus to higher-margin categories and services.

finance.yahoo.com
$TECKMed

Teck Resources stock price target raised to $72 by StoneX on earnings beat

StoneX raised its price target on Teck Resources (NYSE: TECK) to $72 from $67, citing strong Q3 earnings that beat expectations. The company reported adjusted EBITDA of C$2.3B, driven by lower costs and record copper prices. Teck maintained 2026 production guidance and expects a merger to close soon, with potential revenue synergies. The stock is currently trading at $60.87, with a 7.91% return over the past week.

investing.com